期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

放射性核素标记单克隆抗体靶向治疗血液系统恶性肿瘤 被引量：2

暂未订购
导出
摘要 血液系统恶性肿瘤,包括急性白血病（AL）、慢性白血病、恶性淋巴瘤等,是严重威胁人类健康和生命的疾病。虽然骨髓移植是目前根治恶性血液疾病最先进的方法,但由于人类白细胞抗原（HLA）配型成功几率小,无法满足临床的需要,而且并不是所有的血液系统恶性肿瘤患者都可以接受骨髓移植,所以目前对血液系统恶性肿瘤的治疗仍以传统的放疗和化疗为主,再辅以分子靶向治疗。
作者 汪兵 李贵平
机构地区 南方医科大学南方医院核医学科
出处 《放射免疫学杂志》 CAS 2011年第2期144-147,共4页 Journal of Radioimmanology
基金 国家自然基金项目(项目批准号30770601) 广东省科技计划项目(编号2010B060900055)
关键词 血液系统恶性肿瘤 抗体靶向治疗 放射性核素标记 单克隆 恶性血液疾病 人类白细胞抗原 恶性肿瘤患者 分子靶向治疗
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1Kohler G,Milsteln C.Continuous cultures of fused cells secreting antibody of predefined apecifieily[J].J Immunol,2005,174(5):2453.
  • 2Mellstedt H.Monoclonal antibodies in human cancer[J].Drugs Today (Barc),2003,39 Supple C:1-16.
  • 3Feuqier P,van Hoof A,Sebban C,et al.Long-term results of the R-CHOP study of elderly patients with diffuse large B-cell lymphoma:A study by the Group Etude des lymphoma de LAdute[J].J Clin Oncol,2005,18(23):4117-4126.
  • 4夏忠军,王风华,黄慧强,骆卉妍,李宇红,林桐榆,姜文奇,管忠震.含美罗华方案治疗B细胞性惰性淋巴瘤34例报告[J].癌症,2006,25(4):490-494. 被引量：9
  • 5Vose JM,Link BK,Gross BML,et al.Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma[J].J Clin Oncol,2001,19(2):389-397.
  • 6Lundin A,Porwit-MacDonald E,Rossmann D,et al.Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody,CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia[J].Leukema,2004,18(3):484-490.
  • 7Knapp FF.Rhenium-188-a generator-derived radioisotope for cancer therapy[J].Cancer Biother Radiopharm,1998,13(5):337-349.
  • 8李贵平,张辉.^(188)Re标记单克隆抗体的应用研究进展(文献综述)[J].放射免疫学杂志,2003,16(2):113-115. 被引量：4
  • 9Wagner HN,Wiseman GA,Marm MCS,et al.Administration guidelines for radioimmunotherapy of non-Hodgldn's lymphoma with90Y-labelled anti-CD20 monoclonal antibody[J].J Nucl Med,2002,43(2):267-272.
  • 10范我.用于肿瘤治疗的^(90)Y标记单克隆抗体和受体[J].同位素,2002,15(3):168-174. 被引量：2

二级参考文献27

  • 1Gui-PingLi,Yong-XianWang,KaiHuang,HuiZhang,Chun-FuZhang.Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma[J].World Journal of Gastroenterology,2005,11(13):1917-1921. 被引量：1
  • 2Gui-Ping Li,Hui Zhang,Cheng-Mo Zhu,,Jian Zhang,Xu-Feng Jiang.Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma[J].World Journal of Gastroenterology,2005,11(40):6288-6294. 被引量：5
  • 3李贵平,汪勇先,张一帆,张春富.^(188)Re-Herceptin-磁性纳米微粒的体外抗肿瘤作用[J].中华核医学杂志,2007,27(1):16-18. 被引量：7
  • 4Zinzani P L,Pulsoni A,Perrotti A,et al.Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma[J].J Clin Oncol,2004,22 (13):2654-2661.
  • 5Horning S J.Natural history of and therapy for the indolent non-Hodgkin's lymphomas[J].Semin Oncol,1993,20(5):75-88.
  • 6Dillman R O.Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab[J].Semin Oncol,2003,30(4):434-447.
  • 7Hainsworth J D,Litchy S,Burris H A 3rd,et al.Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma[J].J Clin Oncol,2002,20 (20):4261-4267.
  • 8Colombat P,Salles G,Brousse N,et al.Rituximab as single first-line therapy for patients with follicular lymphoma with a low tumor burden:clinical and molecular evaluation[J].Blood,2001,97(1):101-106.
  • 9Mclaughlin P,Grillo-Lopez A J,Link B K,et al.Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-dose treatment program[J].J Clin Oncol,1998,16 (8):2825-2833.
  • 10Walewski J,Kraszewska E,Mioduszewska O,et al.Rituximab(Mabthera,Rituxan) in patients with recurrent indolent lymphoma:evaluation of safety and efficacy in a multicenter study[J].Med Oncol,2001,18(2):141-148.

共引文献12

同被引文献23

  • 1顾兆祥,薛方平,林祥通.^（99m）Tc直接标记IgG及其稳定性研究[J].核技术,1994,17(11):642-645. 被引量：2
  • 2Rosebrough SF, Hartley DF. Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis[J]. J Nucl Med, 1996,37 (8) :1380-1384.
  • 3Alvarez-Diez TM, Polihronis J, Reilly RM. Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and ^111In-DTPA-Bioeytin [ J ]. J Nucl Med, 1996,23 (4) :459 -466.
  • 4Van Gog FB, Visser GWM, Gowrising RWA, et al. Synthesis and evaluation of ^99mTc/^99Tc-MAG3 -Biotin conjugates for antibody pretargeting strategies[J]. J Nucl Med,1998,25(7) :611-619.
  • 5Ratei R, Sperling C, Karawajew L, et al. Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute |ymphoblastic leukemia [ J ]. Ann Hematol, 1998, 77(3): 107-114.
  • 6Pagel JM, Matthews DC, Kenoyer A, et al. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia[ J]. Cancer Res, 2009, 69 ( 1 ) : 185-192.
  • 7Iznaga-Escobar N, Ramirez IL, Izquierdo JC, et al. 8SRe- labeled anti-epidermal growth factor receptor humanized monoclonal antihody h-R3 : labeling conditions, Or vitro and in vivo stability[J]. Methods Find Exp Clin Pharmacol, 2003, 25 (9) : 703-711.
  • 8Luo TY, Cheng PC, Chiang PF, et al. mRe-HYNIC- trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells[J]. Ann Nucl Med, 2015, 29(1):52-62.
  • 9Pillai MR, Dash A, Knapp FF Jr. Rhenium-188: availability from the lSSw/lSSRe generator and status of current applications [J]. Curr Radiopharm, 2012, 5(3): 228-243.
  • 10Liitje S, Rijpkema M, Goldenberg DM, et al. Pretargeted dual- modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer [ J ]. Cancer Res, 2014, 74(21 ) :6216-6223.

引证文献2

放射免疫学杂志
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部